The rise of Viagra initially drove a boom for major pharmaceutical companies, however recent shifts present a complicated scenario for investors. Generic competitors are eroding earnings, and persistent legal battles add additional risk to the situation. While specific companies might still benefit from related products, the overall direction sugge